518 related articles for article (PubMed ID: 9605174)
21. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
22. Fas-Fas ligand-mediated apoptosis within aqueous during idiopathic acute anterior uveitis.
Dick AD; Siepmann K; Dees C; Duncan L; Broderick C; Liversidge J; Forrester JV
Invest Ophthalmol Vis Sci; 1999 Sep; 40(10):2258-67. PubMed ID: 10476791
[TBL] [Abstract][Full Text] [Related]
23. The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.
Houston AM; Michael-Robinson JM; Walsh MD; Cummings MC; Ryan AE; Lincoln D; Pandeya N; Jass JR; Radford-Smith GL; O'Connell J
Hum Pathol; 2008 Feb; 39(2):243-50. PubMed ID: 17961631
[TBL] [Abstract][Full Text] [Related]
24. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Yao H; Song E; Chen J; Hamar P
Br J Cancer; 2004 Nov; 91(9):1718-25. PubMed ID: 15494722
[TBL] [Abstract][Full Text] [Related]
25. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast.
Yakirevich E; Maroun L; Cohen O; Izhak OB; Rennert G; Resnick MB
J Pathol; 2000 Oct; 192(2):166-73. PubMed ID: 11004692
[TBL] [Abstract][Full Text] [Related]
27. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
28. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
29. Induction of Fas-mediated apoptosis in a human renal epithelial cell line by interferon-gamma: involvement of Fas-mediated apoptosis in acute renal rejection.
Akasaka Y; Ishikawa Y; Kato S; Ishii T; Masuda T; Fujita K; Yamada T; Kawamura S
Mod Pathol; 1998 Nov; 11(11):1107-14. PubMed ID: 9831209
[TBL] [Abstract][Full Text] [Related]
30. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
31. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
Lim SC
Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
[TBL] [Abstract][Full Text] [Related]
32. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
33. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.
Hughes SJ; Nambu Y; Soldes OS; Hamstra D; Rehemtulla A; Iannettoni MD; Orringer MB; Beer DG
Cancer Res; 1997 Dec; 57(24):5571-8. PubMed ID: 9407969
[TBL] [Abstract][Full Text] [Related]
34. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
35. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.
Yakes FM; Wamil BD; Sun F; Yan HP; Carter CE; Hellerqvist CG
Cancer Res; 2000 Oct; 60(20):5740-6. PubMed ID: 11059768
[TBL] [Abstract][Full Text] [Related]
36. Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.
Zietz C; Rumpler U; Stürzl M; Löhrs U
Am J Pathol; 2001 Sep; 159(3):963-70. PubMed ID: 11549589
[TBL] [Abstract][Full Text] [Related]
37. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
38. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
39. Fas ligand expression in human pancreatic cancer.
Ohta T; Elnemr A; Kitagawa H; Kayahara M; Takamura H; Fujimura T; Nishimura G; Shimizu K; Yi SQ; Miwa K
Oncol Rep; 2004 Oct; 12(4):749-54. PubMed ID: 15375495
[TBL] [Abstract][Full Text] [Related]
40. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
